RAMM Pharma Corp. focuses on the research, development, and sale of cannabinoid-based pharmaceuticals and related products. The company faces significant financial challenges, evidenced by a low gross margin of 5.6% and negative EBITDA and net margins, indicating operational inefficiencies. Additionally, a current ratio of 0.28 suggests liquidity issues, while a debt/equity ratio of 0.05 indicates low leverage. The sharp 50% drop in stock price raises concerns about market confidence. Overall, RAMM Pharma's financial health appears precarious, necessitating strategic improvements for future viability.
Loading financial metrics...
Company has $147K in cash but burned $315K last quarter. At this burn rate, only 0.5 quarters of runway remain without additional financing.
Revenue fell 66.4% year-over-year from $3.8M to $1.3M. The decline has persisted for multiple quarters.
Company posted a loss of $-9.1M over the last year, representing 715.6% of revenue.
Debt increased 510.2% from $28K to $170K while revenue growth remained modest.
Gross margin expanded by 52.9 percentage points, indicating improved pricing power or cost efficiency.
Exceptional gross margin of 76.5% indicates strong pricing power and competitive moat.
Low debt-to-revenue ratio of 13.4% indicates conservative financial management.
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q3 (July 31, 2026)